BML Investment Partners Discloses New Stake in Aclaris Therapeutics
Ticker: ACRS · Form: SC 13G · Filed: Jan 16, 2024 · CIK: 1557746
| Field | Detail |
|---|---|
| Company | Aclaris Therapeutics, INC. (ACRS) |
| Form Type | SC 13G |
| Filed Date | Jan 16, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, new-stake, SC-13G
TL;DR
**BML Investment Partners just bought a big chunk of Aclaris Therapeutics.**
AI Summary
BML Investment Partners, L.P. has disclosed a new significant stake in Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a pharmaceutical company, as of January 11, 2024. This filing indicates that BML Investment Partners, L.P. now beneficially owns a substantial portion of Aclaris's common stock. This matters to current and potential Aclaris shareholders because a large institutional investor taking a new position can signal confidence in the company's future prospects or potentially lead to increased scrutiny and activist involvement.
Why It Matters
A new institutional investor taking a significant position can influence stock performance and company strategy, signaling potential shifts in market perception or future corporate actions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of a new ownership stake and does not inherently indicate negative risk, but rather increased institutional interest.
Analyst Insight
Investors should monitor Aclaris Therapeutics for any further disclosures from BML Investment Partners, L.P. or other institutional investors, as a significant stake could precede engagement with management or a change in strategy.
Key Players & Entities
- BML Investment Partners, L.P. (company) — the reporting person acquiring shares
- Aclaris Therapeutics, Inc. (company) — the subject company whose shares were acquired
- January 11, 2024 (date) — the date of the event requiring the filing
- Delaware (company) — place of organization for BML Investment Partners, L.P.
- $0.00001 (dollar_amount) — par value of Aclaris Therapeutics Common Stock
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person in this SC 13G filing is BML Investment Partners, L.P., as stated under 'NAMES OF REPORTING PERSONS'.
What is the subject company whose securities are being reported?
The subject company is Aclaris Therapeutics Inc, as indicated under 'Name of Issuer'.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock, $0.00001 par value, of Aclaris Therapeutics Inc is 00461U105.
When was the date of the event that required this filing?
The date of the event which required the filing of this statement was January 11, 2024.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(c), as indicated by the checked box on the cover page.
Filing Stats: 873 words · 3 min read · ~3 pages · Grade level 7.7 · Accepted 2024-01-16 17:24:31
Key Financial Figures
- $0.00001 — s Inc (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securiti
Filing Documents
- bml13g.htm (SC 13G) — 52KB
- 0001616824-24-000009.txt ( ) — 53KB
(a)
Item 1(a). Name of Issuer: Aclaris Therapeutics, Inc.
(b)
Item 1(b). Address of Issuer's Principal Executive Offices: 701 Lee Road, Suite 103, Wayne, PA 19087
(a)
Item 2(a). Name of Person Filing: BML Investment Partners, L.P.
(b)
Item 2(b). Address of Principal Business Office or, if none, Residence: 65 E. Cedar - Suite 2 Zionsville, IN 46077
(c)
Item 2(c). Citizenship: Delaware
(d)
Item 2(d). Title of Class of Securities: Common Stock, par value $0.00001 per share
(e)
Item 2(e). CUSIP Number: 00461U105 Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n): (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ . Item 4. (a) Amount beneficially owned: 4,500,000 (b) Percent of class: 6.4 (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 4,500,000 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 4,500,000 Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class